Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade D 154.5 0.00% 0.00
VRTX closed up 1.85 percent on Tuesday, June 19, 2018, on approximately normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Flat Up
See historical VRTX trend table...

Date Alert Name Type % Chg
Jun 19 50 DMA Resistance Bearish 0.00%
Jun 19 Multiple of Ten Bullish Other 0.00%
Jun 19 Outside Day Range Expansion 0.00%
Jun 18 Evening Star Bearish 1.85%
Jun 18 Fell Below 50 DMA Bearish 1.85%
Jun 18 Gapped Down Weakness 1.85%
Jun 15 200 DMA Resistance Bearish -0.34%
Jun 15 50 DMA Support Bullish -0.34%
Jun 15 NR7 Range Contraction -0.34%
Jun 15 Up 3 Days in a Row Strength -0.34%

Older signals for VRTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Is VRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 178.25
52 Week Low 125.5
Average Volume 1,539,923
200-Day Moving Average 155.2643
50-Day Moving Average 154.6106
20-Day Moving Average 152.553
10-Day Moving Average 151.003
Average True Range 3.766
ADX 17.55
+DI 17.42
-DI 23.94
Chandelier Exit (Long, 3 ATRs ) 146.922
Chandelier Exit (Short, 3 ATRs ) 155.368
Upper Bollinger Band 160.1327
Lower Bollinger Band 144.9733
Percent B (%b) 0.63
BandWidth 9.937137
MACD Line -0.5779
MACD Signal Line -1.1778
MACD Histogram 0.5999
Fundamentals Value
Market Cap 38.96 Billion
Num Shares 252 Million
EPS 1.04
Price-to-Earnings (P/E) Ratio 148.56
Price-to-Sales 17.01
Price-to-Book 21.57
PEG Ratio 1.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 162.62
Resistance 3 (R3) 161.91 158.49 161.26
Resistance 2 (R2) 158.49 156.43 158.85 160.81
Resistance 1 (R1) 156.50 155.15 157.50 157.21 160.36
Pivot Point 153.08 153.08 153.58 153.44 153.08
Support 1 (S1) 151.09 151.02 152.09 151.80 148.64
Support 2 (S2) 147.67 149.74 148.03 148.19
Support 3 (S3) 145.68 147.67 147.74
Support 4 (S4) 146.39